Adverum Biotechnologies, Inc. (ADVM) NASDAQ
4.36
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.36
+0(+0.00%)
Currency In USD
| Previous Close | 4.36 |
| Open | 4.24 |
| Day High | 4.36 |
| Day Low | 4.24 |
| 52-Week High | 6.07 |
| 52-Week Low | 1.78 |
| Volume | 675,984 |
| Average Volume | 724,344 |
| Market Cap | 96.26M |
| PE | -0.51 |
| EPS | -8.57 |
| Moving Average 50 Days | 4.41 |
| Moving Average 200 Days | 3.48 |
| Change | 0 |
Data not available
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a LiquidationREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stag
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026)ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc.
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire Inc.
Aug 06, 2025 8:01 PM GMT
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Pr